Skip to main content
. 2015 Sep 10;6(35):38429–38439. doi: 10.18632/oncotarget.5193

Table 2. Treatment efficacy of the patients.

Efficacy No. of patients (%)
Response
 Overall response rate 18 (90%)
 Disease control rate
  Complete response 5 (25%)
  Partial response 13 (65%)
  Stable disease 2 (10%)
  Progressive disease 0 (0)
Survival
 Median (months) 14.0 (95% CI: 10.0–17.9)
 1 year (%) 58.2
 Progression-free survival
  Median (months) 7.0 (95% CI: 0–17.2)